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INTRODUCTION
Despite increasing understanding of pain mechanisms and
ongoing research in pain therapy, improved postoperative
analgesia is a challenge for anaesthesiologists and every
person involved in patient care postoperatively. The effi-
cacy of postoperative pain therapy after major joint replace-
ment surgery is one of the most important factors in func-
tional outcome. Good postoperative analgesia is associated
with less postoperative physiological disturbances and im-
provement in postoperative morbidity and rehabilitation.
This paper proposes the epidural application of glucocortic-
oids as a component of balanced preventive multimodal an-
algesia for acute postoperative pain relief after knee re-
placement surgery. An increasing number of publications
concerning the use of steroids in acute pain relief has ap-
peared in recent years. The development of adrenocortical
physiology and pharmacology has advanced exogenous
glucocorticoids to become one of the most widely used
classes of drugs in clinical medicine (Schimmer et al.,
1996). Glucocorticoids have powerful anti-inflammatory
characteristics (Ontjes et al., 1995; Ferreira et al., 1997;
Barnes et al., 1998). In the last years, several theories about
the genomic effects of glucocorticoids have been devel-
oped. The inhibition of inflammation involves decreased
stability of messenger ribonucleic acid (mRNA) for the
genes of inflammatory proteins, such as vascular endothelial
growth factor and cyclooxygenase (COX)–2. Gluco-
corticoid-induced effects that require protein synthesis have
about two hours latency of onset; therefore, to have advan-
tages in anti-inflammatory and pain reductive effects, it
seems to be necessary to inject glucocorticoids preopera-
tively. At the same time, there are reports of rapid onset of
analgesic and antihyperalgesic effects of glucocorticoids
(Romunstad et al., 2004). It is now accepted that
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Despite many achievements during the last decade, postoperative pain remains the dominant
complaint after major surgery and has great potential to be influenced by the anaesthesiologist.
Reports suggest that short-term effective anaesthesia and analgesia can have long-lasting bene-
ficial effects on recovery from surgery. The aim of our study is to compare the effect of epidural
analgesia, using different compositions, including glucocorticoids (methylprednisolone), and habit-
ual composition of bupivacaine-morphine, in regard to analgesic and anti-inflammatory properties.
A total of 129 patients participated in the study in four different treatment groups: patients from
Group I received glucocorticoid methylprednisolone succinate and long-acting opioid morphine
hydrochloride, Group II received local anaesthetic bupivacaine hydrochloride and morphine hy-
drochloride, Group III received methylprednisolone succinate and short-acting opioid fentanyl,
and Group IV received glucocorticoid methylprednisolone succinate. We obtained good analgesic
profiles in all groups. However, significantly better results were achieved using the combination of
methylprednisolone and morphine. Epidural methylprednisolone in dose 80 mg/24 h is more ef-
fective, compared to the conventional local anaesthetics-opioid composition, when administered
as a part of multimodal preventive postoperative analgesia after major joint replacement surgery.
Epidural methylprednisolone has a reliable anti-inflammatory and immunomodulatory potential. It
attenuates profiles of acute inflammatory response markers as Interleukin-6 and C-reactive pro-
tein and stress hormone cortisol. The novelty of this study was application of epidural glucocorti-
coids for acute postoperative pain relief as part of daily perioperative care. By developing studies
on anti-inflammatory and immunomodulatory properties of glucocorticoids, we expect to improve
patient rehabilitation in the postoperative period.
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glucocorticoids, in addition to the traditional genomic ef-
fects which take hours, show rapid effects by acting on
membrane receptors (Falkenstein et al., 2000). These rapid
nongenomic effects of glucocorticoids are due, at least in
part, to decreased glutamate release and increased release of
-aminobutyric acid and endocannabinnoids (Di et al.,
2005). Recent work suggests that glucocorticoids can have
rapid effects on inflammation that are not mediated by
changes in gene expression. The best described nongenomic
mechanism involves the activation of endothelial nitric ox-
ide synthetase (eNOS) (Hafezi-Moghadam et al., 2002).
Small proteins called cytokines have a major role in the in-
flammatory response to surgery, trauma and pain mecha-
nisms. They have local effect of mediating and maintaining
the inflammatory response to tissue injury and they also ini-
tiate some of the systemic changes that may occur. The
main cytokines released are interleukin-1 (IL-1), tumour
necrosing factor (TNF-) and interleukin-6 (IL-6); they are
responsible for inducing the systemic changes known as the
acute phase response. Administration of glucocorticoids af-
ter incision suppresses the release of proinflammatory
cytokines. Varying doses of glucocorticoids do not lead
simply to varying degrees of inflammation suppression;
considerably more, they can exert a full range of effects
from permissive to stimulatory to suppressive (Yeager et
al., 2004).
Glucocorticoids are efficacious in perioperative manage-
ment and particularly in postoperative pain relief as adju-
vant analgesics (Watanabe et al., 1994). Glucocorticoids
have potent anti-inflammatory effects and reduce pain and
swelling after oral operations (Skjelberd et al., 1982), ortho-
paedic and spinal operations (Holte et al., 2002), laparo-
scopic (Bisgaard et al., 2003), major abdominal (Schulze et
al., 1992, 1998) and artroscopic procedures (Kizilkaya et
al., 2005) as well as after lumbar disc surgery (Lavyne et
al., 1992; Glasser et al., 1993; Langmayr et al., 1995).
There are many publications supporting high doses of intra-
venous glucocorticoids during major cardiac, abdominal
and orthopaedic surgery (Nagelshmidt et al., 1999; Sauer-
land et al., 2000; Yeager et al., 2004, 2005), which decrease
stress response to major surgery. We have found recent ob-
servational studies (Marinangeli et al., 2002; Gilron et al.,
2004; Salerno et al., 2006, Kehlet, 2007) suggesting wider
application of glucocorticoids for postoperative pain relief.
Findings in experimental pain models (Romunstad et al.,
2004; Stubhaug et al., 2007) help to understand the research
results on the effects of methylprednisolone on reduction of
pain, postoperative nausea and vomiting, fatigue and late
wound hyperesthesia, as well as sustained analgesic effect
and reduced opioid requirements for 1–3 days after surgery
(Romunstad et al., 2004, 2006).
Patients who have a herniated disk, spinal stenosis or failed
back surgery may benefit from epidural steroid injection
with methylprednisolone acetate (Manchikanti et al., 2002;
Singh et al., 2002). Reports on thousands of patients indi-
cate that epidural glucocorticoid injections are relatively
straightforward and safe in the treatment of back pain
(Carette et al., 1997).
Anaesthesiologists began to use steroids epidurally mostly
for backache treatment common after surgery or epidural
needle insertion. Soon after, they discovered significant re-
duction in postoperative analgesia requirements. McNeil et
al. (1995) administered epidurally separately saline solu-
tion, morphine, methylprednisolone and a combination of
morphine and methylprednisolone for pain reduction after
spinal stenosis surgery or herniated intervertebral disc.
Wang et al. (1998) gave dexametasone epidurally after
muiltiple epidural needle insertion. The severity and dura-
tion of postepidural backache also significantly decreased in
those patients. Since patients complained about back pain
after surgical interventions—mostly related to bad position-
ing or pre-existing discogenic disease—on the supposition
that postoperative pain should be treated preventively, pa-
tients received 1 mg morphine with 80 mg of methylpred-
nisolone epidurally directly after surgery (Joos et al., 1993).
Preoperative epidural administration of dexamethasone 5
mg, with or without bupivacaine, reduced postoperative
pain and morphine consumption following laparoscopic
cholecistectomy (Thomas et al., 2006). Studies about
epidural methylprednisolone-morphine compositions in or-
thopaedic knee surgery showed comparable or even supe-
rior analgesic effect with bupivacaine–morphine mixture
(Golubovska et al., 2007).
We can be quite certain in saying that methylprednisolone
suspension has no neurotoxic effect on normal nerves and in
the epidural space (Johansson et al., 1995; Delaney et al.,
1980).
The aim of our study is to compare pain relief by epidural
route of analgesia, using different combinations that include
glucocorticoids (methylprednisolone), with habitual compo-
sition of bupivacaine-morphine mixture, in regard to anal-
gesic and anti-inflammatory properties of glucocorticoids.
The objectives for our research were:
1) To determine whether perioperative use of epidural
methylprednisolone is a sufficient analgesic, when given in
small doses of opioids or without them, to achieve an ac-
ceptable pain verbal rating score (0–4).
2) To determine whether perioperative use of epidural
methylprednisolone can improve endocrine and immune re-
sponse to surgery.
3) To compare the quality of pain relief and side effects of
methylprednisolone-morphine, methylprednisolone-fentanyl
combinations and methylprednisolone with bupivacaine-
morphine combination after knee replacement surgery.
MATERIALS AND METHODS
The study was performed at the Department of Anaesthesi-
ology and Orthopaedics of the Hospital of Traumatology
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and Orthopaedics. The Ethics Committee of Rîga Stradiòð
University approved the study protocols. Informed consent
was obtained from all patients. Prospective randomised
single-blind trial was conducted from November 2006 to
May 2008. A total of 135 patients undergoing knee replace-
ment surgery were included in this study. Patients with dia-
betes mellitus, infectious problems, rheumatoid arthritis,
gastrointestinal ulcerations and those who used glucocorti-
coids were excluded from the study. Patients were randomly
assigned to one of the four study groups. Randomisation
was performed in active concurrent control groups.
Patients of Group I received glucocorticoid methylpredniso-
lone succinate and long-acting opioid morphine hydrochlo-
ride (n = 33).
Patients of Group II received local anaesthetic bupivacaine
hydrochloride and morphine hydrochloride (n = 41).
Patients of Group III received methylprednisolone succinate
and short-acting opioid fentanyl (n = 31).
Group IV received methylprednisolone succinate (n = 30).
Combined spinal-epidural anaesthesia (CSEA) was per-
formed to all patients. Spinal bupivacaine 0.5% was in-
jected intratecally for surgical analgesia. At the end of sur-
gery and during their stay in the postanaesthesia care unit
(PACU), patients received different epidural analgesic com-
positions in accordance with the protocol and time sched-
ules (See Table 1). For each recruited patient in groups
I–IV, a trained nurse followed the instructions and prepared
the study drugs. All of the study preparations were masked
by dilution to the same volume of saline (10 ml). If analge-
sia was unsatisfactory, the rescue analgesic was bupivacaine
0.5% 5 ml (25 mg) epidurally. Rescue medication was
given on patient request or if pain exceeded 4 by a 10-point
numeral verbal rating scale (NVRS).
Sensory level, motor blockade, pain score, time until the
first rescue analgesic, the amount of additional bupivacaine,
mean arterial pressure and pulse rate were assessed after in-
troduction for 24 hours. Changes of glucose, C-reactive pro-
tein, IL-6 and cortisol were measured before incision and 24
h after the first epidural injection. Side effects were regis-
tered. Patients assessed their experience of postoperative
pain at rest by indicating a number on the eleven-point
NVRS between the extremes 0 cm—no pain and 10 cm—
the worst pain imaginable at 0, 2, 4, 6, 8, 12, 16, 20 and 24
hours. A patient questionnaire was used to evaluate their
satisfaction. Statistical analysis was performed using
ANOVA, Students t-test, Wilcoxon Signed Ranks test,
Kruskal–Wallis test, Pearson Chi-Square test.
RESULTS
Six patients were excluded from study due to accidental
evacuation of epidural catheter or major motor blockade.
Statistical analysis was performed for 129 patients. Patients
in all study groups were statistically comparable (P > 0.05)
(See Table 2).
Although patients in all treatment groups had very accept-
able pain scores during the entire period of measurements,
the score differed among treatment groups. 24-hour pain in-
tensity was quite similar in all groups, with the lowest score
in Group I (see Fig. 1). Regarding the intensity of pain at
each observation time, Group I succeeded better than others
in the periods just before the first planned epidural injection
and during night sleep. Multivariate NVRS at time 3
(6 hours from the first epidural injection) differed among
groups: I = 0.5 ± 0.6; II = 1.2 ± 0.9; III = 1.3 ±1.1; IV=1.4
± 0.8 points (P < 0.001). Multivariate NVRS at time 5
(which means 12 hours after the first epidural injection): I =
0.8 ± 1.1; II = 1.0 ± 1.0; III =1.4 ± 1.4; IV = 1.1±1.0 points
(P < 0.05). The mean pain score for all measurements
across times did not differ significantly (P > 0.05) between
groups: Group I was 0.6 ± 0.4, in Group II – 0.8 ± 0.4, in
Group III 0.9 ± 0.5, and in Group IV 0.8 ± 0.4. The patients
in Group I required significantly less additional bupivacaine
administered epidurally. The number of additional
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T a b l e 1
EPIDURAL ANALGESIC COMPOSITIONS IN DIFFERENT TREATMENT GROUPS (I–IV)
Time I II III IV






























T a b l e 2




I II III IV
N valid 32 39 29 29
Age (years) 70.1±7.9 67.8±6.8 68.7±8,1 66.2±10.1
Sex (m/f) 6/26 5/34 6/23 5/24
Body-mass
index (BMI)(kg/m2)
29.4±5.1 32.4±5.3 30.2±5.6 30.9±7.4
Age and BMI (body mass index) are expressed as mean ±SD
bupivacaine injections (25 mg) ranged from 0–2 times
(mean 0.66 ± 0.70) in Group I, 0–4 times in Group II (mean
1.2 ± 1.0), 0–4 times in Group III (mean 2.1 ± 1.2), 0–5
times in Group IV (mean 2.2 ± 1.2) (P < 0.05). During the
observation period, 15 patients (47%) did not require
epidural bupivacaine injections for pain relief in Group I,
while only two patients obtained such prolonged pain relief
in Groups III and IV (9.4%, 6.2%). The amount of
bupivacaine required for breakthrough pain to reach suffi-
cient analgesia was significantly different in all groups. In
Group I, the consumption of additional bupivacaine amid
patients who needed it during the first 24 hours postopera-
tively was 31.0 ± 10.9 mg, in Group II 40.5 ± 19.4 mg, in
Group III 58.6 ± 26.4 mg, and in Group IV 57.4 ± 27.5 mg
(mean± SD, P < 0.05) (see Table 3). There were no signifi-
cant differences in time until the first rescue analgesic
among groups in patients who needed them.
Not many cardiovascular, neurological and other complica-
tions were observed. One patient from Group II died from
myocardial infarction on the fifth postoperative day. One
patient from Group I developed aseptic inflammation in the
knee six months after surgery. The problem was resolved by
means of conservative methods. Minor side effects were not
statistically different among the groups.
Overall satisfaction rate was very good: 8.5 ± 1.2 points.
The mean satisfaction rates were: 8.7 ± 1.0 in Group I, 8.6 ±
1.3 in Group II, 8.8 ± 1.0 in Group III, 8.7 ± 1.0 in Group
IV (mean ± SD, P > 0.05).
Regarding anti-inflammatory and hormonal responses to an-
algesia, we observed a significant difference in IL-6 and
CRP postoperative production among the study groups. The
increase was similar in the methylprednisolone groups (I,
III, IV), while being significantly higher in Group II (see
Table 4). The mean IL-6 levels were significantly lower in
the methylprednisolone groups compared to bupivacaine
group on postoperative day I (P < 0.001). There was an in-
crease in the plasma concentration of C-reactive protein in
all groups following surgery. The mean C-reactive protein
levels were significantly higher in the bupivacaine group
compared to methylprednisolone groups on postoperative
day I (P < 0.05). We performed Pearson’s correlation
analysis between IL-6 and C-reactive protein levels in the
different treatment groups and found significant correlations
between IL-6 and C-reactive protein concentrations in
Groups I, II and III, but not in Group IV. Cortisol produc-
tion decreased significantly postoperatively in the methyl-
prednisolone groups (P < 0.05) (see Table 4).
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Fig. 1. Pain during the observation period, ex-
pressed as numeral verbal rating scale (NVRS)
from 0 to 10.
T a b l e 3
CHARACTERISTICS OF POSTOPERATIVE PAIN RELIEF: NUMBER
OF RESCUE INJECTIONS AND ADDITIONALLY INJECTED
BUPIVACAINE
Groups I II III IV
Number of rescue
injections
0.6 ± 0.7 1.2 ± 1.0 2.1 ± 1.2 2.1 ± 1.2
Additional bupivacaine
(mg)
30.8 ± 10.9 40.5 ± 19.3 58.6 ± 26.4 57.4 ± 27.5
Data are presented as mean ± SD
T a b l e 4
PRODUCTION OF IL-6, CRP, CORTISOL, AND GLUCOSE IN THE PERIPHERAL BLOOD IN DIFFERENT PAIN TREATMENT GROUPS
Groups Glucose mmol/l CRP mg/dl IL-6 pg/ml Cortisol g/dl
before after before after before after before after
I 5.3±1.0 7.5± 1.3 6.0±10.5 38.2±28.1 22.1±49.9 65.6±50,9 13.0±4.4 6.4±3.4
II 5.5±0.9 7.5±1.7 4.9±4.7 71.6±37.7 14.1±32.4 267.8±262 12.8±3.7 14.3±6.9
III 5.1±0.6 7.7±1.8 3.9±3.9 37±21.8 9.8±21.9 61.7±57.2 13.3±5.6 5.9±4.1
IV 6.2±3.8 8.9±2.6 6.0±10.3 30.4±14.9 24.9±22.6 37.3±29.6 11.9±4.9 5.5±3.9
There was no statistically significant difference in glucose
levels before and after surgery among groups, except Group
IV (See Table 4).
DISCUSSION
We compared our study with other outcomes after knee re-
placement surgery, using epidural analgesia. Muldoon et al.
(1998) compared 0.2% ropivacaine or 0.2% bupivacaine by
epidural infusion for 24 h after operation. Pain by visual
analogue scale (VAS) at rest was low in both groups; the
median VAS was 0–13.3 mm (by 100 mm VAS) for the
ropivacaine group and 0–0.5 mm for the bupivacaine group.
Over 24 h of infusion, the estimated (ropivacaine–bupiv-
acaine) difference in wound pain at rest was 5.6 mm (P <
0.05) and on passive movement—11.6 mm (P < 0.05).
Himmelseher et al. (2001) added ketamine to epidural injec-
tions prior to surgery. After lumbar epidural anaesthesia
with ropivacaine (10 mg/ml, 10–20 ml), patients received
0.9% epidural saline or 0.25 mg/kg epidural S(+)-ketamin
10 min before surgical incision. During the first 8 h after
surgery, VAS pain rating was similar among groups; never-
theless, the mean VAS for the ketamin group was below 1,
whereas for the ropivacaine group—between 1 and 3 at rest.
Buvendranan et al. (2006) studied the effects of COX-2 in-
hibitors on pain management after total knee replacement.
CSEA was performed, and the infusion of fentanyl and bu-
pivacaine was started, allowing patients to give themselves
bolus doses at their discretion to maintain VAS between 2
and 4. The research group received additional rofecoxib.
Postoperative median pain scores were: 3.5 (2.7–4.3) in the
patient-controlled epidural analgesia group; 2.2 (1.4–3.2) in
the rofecoxib group. Pain scores were significantly lower in
our study.
Some studies have not found analgesic properties of
epidural glucocorticoids.
Lavyne et al. (1992) reported that patients undergoing
microdiscectomy, who received epidural methylprednisol-
one after surgery, did not have reduction of pain compared
to the control group. Blanloeil et al. (2001) compared
epidural infusion of methylprednisolone 1.5 mg/kg and pla-
cebo after posterolateral thoracotomy. Additional morphine
analgesia was administered by intravenous patient-con-
trolled analgesia. There was no significant difference for
morphine requirements between the groups. Reikeras et al.
(2008) studied glucocorticoids and cytokine production dur-
ing surgery in orthopaedic patients, administering high
doses of methylprednisolone intravenously (10 mg/kg) and
did not find any significant effect of glucocorticoids on
postoperative pain. In major abdominal or thoracic surgery,
the analgesic and other outcome effects of perioperative
glucocorticoids are promising but still debatable; therefore,
no definite conclusions can be drawn yet. Studies on major
abdominal surgery (Apfel et al., 2004) have not been able to
document any definite analgesic effect of glucocorticoids.
The difference in pain among groups did not differ much 24
hours after surgery with clearly better result in Group I. The
postoperative period may reflect the interval required for the
sensitising effects of surgery to become fixed, or it may re-
flect peripheral inputs from the operated knee, obscuring the
spinal component of nociception in the earlier postsurgical
period. In particular, the crucial time interval appears to be
from the first minutes to hours after surgery, and then there
is a second phase of inflammatory injury with interleukins
and acute phase proteins rising up. We cannot decisively
state that preventive analgesia was shown. We can only
speculate that methylprednisolone blocked pain sensitisa-
tion during the entire observation period, while its antino-
ciceptive effects were accomplished by the action of mor-
phine and bupivacaine during the first postoperative hours.
On the other hand, pain did not become clinically relevant
before patient mobilisation was started. We suggest that the
use of small doses of epidural methylprednisolone with
morphine before pain begins may decrease injury-induced
pain sensitisation, and thus provide better analgesia in the
postoperative period than that achieved with a dose of local
anaesthetics with morphine in the epidural space.
The concomitant administration of methylprednisolone and
morphine results in a synergistic analgesic effect. Sustained
postoperative opioid sparring effect and pain relief continu-
ing for three days after one single dose of glucocorticoids
(methylprednisolone or dexamethasone) have been reported
(Romundstad et al., 2004). A prolonged opioid sparring ef-
fect, continuing for at least 72 hours, indicates a prolonged
effect of methylprednisolone on postoperative inflammatory
pain, which could be explained by the duration of biological
anti-inflammatory activity of methylprednisolone—esti-
mated to be about 36 hours after intravenous injection
(Holte et al., 2004), although it might be different after
epidural injection.
We did not find any similar studies about epidural gluco-
corticoids and attenuated neuroendocrine and immune re-
sponse. Reikeras et al. (2008) carried out a study of intrave-
nous high-dose methylprednisolone (10 mg/kg) in
orthopaedic surgery and found that glucocorticoids signifi-
cantly reduced the increases in IL-6 and C-reactive protein.
The imbalance between proinflammatory and anti-inflam-
matory cytokines determines the development of stress re-
sponse to surgery and should help the physician to compose
a therapeutic strategy. In fact, recent clinical studies have
shown that both the initial uncontrolled hyperinflammation
and the continued cell-mediated immunosuppression repre-
sent primary targets to counteract the post-surgery immune
dysfunction (Menger et al., 2004). There are many studies
investigating the role of IL-6 in the development of pain,
and it is well reviewed that IL-6 is related to the develop-
ment of pain and that intrathecal anti-IL-6 antibody will at-
tenuate this reaction (De Leo et al., 1996). Pain is transmit-
ted from the periphery to higher brain areas, from where the
pain messages can be either suppressed (analgesia), relayed
unaltered, or amplified (hyperalgesia). Pain modulation oc-
curs in the dorsal horns of the spinal cord, where peripheral
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nerves relay sensory information to pain transmission neu-
rons. Both analgesia and hyperalgesia originate at the point
where the periphery meets the CNS. Neutralizing IL-6 or
changes in the IL-6 pathway alter the perception of pain.
IL-6 induces pain by releasing COX products and inducing
arachidonic acid release. This mechanism can be aborted by
glucocorticoids. Injecting glucocorticoids epidurally influ-
ence IL-6 production both generally and locally; notably,
only very small amounts are needed for good effect.
Pearson’s correlation test did not show any statistically sig-
nificant correlation between IL-6 concentration and the
mean pain intensity, which might be explained by wrong
timing. In any case, it is difficult to interpret the absence of
correlation between IL-6 level and intensity of pain from
one measurement. We chose a 24-hour time interval be-
cause it was described as the peak level of IL-6 and
C-reactive protein after major orthopaedic surgery (both hip
and knee) in some literature (Hall et al., 2000) and major
orthopaedic surgery of spine in others (Reikeras et al.,
2008).
In conclusion:
1) Epidural analgesia produced reliable pain relief in all
study groups. Patients were highly satisfied with knee sur-
gery performed under epidural analgesia. However, signifi-
cantly better results were achieved when using the combina-
tion of methylprednisolone and morphine (Group I).
2) Epidural methylprednisolone 80 mg/24 h is effective as a
part of multimodal preventive postoperative analgesia after
major joint replacement surgery. Compared to habitual local
anaesthetics and opioid mixture, it shows a similar or even
better analgesic effect (in combination with morphine).
3) Adding fentanyl in epidural mixtures had only a minor
effect on postoperative analgesia after knee replacement
surgery with no significant difference from that achieved
with addition of saline.
4) Epidural methylprednisolone has marked morphine spar-
ring effect.
5) Epidural methylprednisolone has marked anti-inflam-
matory and immunomodulatory potential. The altered IL-6,
C-reactive protein and cortisol values among the groups
may be a direct effect of methylprednisolone, considering
that the same type of surgery—i.e. producing similar de-
grees of tissue damage—and anaesthetic regimens were
used.
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DAÞÂDU PÇCOPERÂCIJAS EPIDURÂLO ANALGÇZIJAS KOMPOZÎCIJU IETEKME UZ ATSÂPINÂÐANU UN ATBILDI
ÍIRURÌISKAJAM STRESAM PÇC CEÏA ENDOPROTEZÇÐANAS OPERÂCIJÂM
Neraugoties uz sasniegumiem pçdçjos gados, akûtâs pçcoperâcijas sâpes ir visbieþâkâ pacientu sûdzîba pçc íirurìiskas iejaukðanâs, taèu tâs
ir potenciâli visvairâk ietekmçjamas perioperatîvajâ periodâ. Mûsu pçtîjuma mçríis bija salîdzinât epidurâlo atsâpinâðanu pçc ceïa
endoprotezçðanas operâcijâm, izmantojot daþâdas medikamentu kompozîcijas. Mçs salîdzinâjâm grupas, kuru kompozîcijas ietvçra
glikokortikoîdu metilprednizolonu kombinâcijâs ar daþâdiem opioîdiem un bez tiem ar ierasto lokâlâ anestçtiía bupivakaîna un morfîna
kompozîciju un pçtîjâm to ietekmi uz pçcoperâcijas atsâpinâðanu un neiroendokrîno un imûno atbildi íirurìiskajam stresam. Pçtîjumu
pabeidza 129 pacienti èetrâs terapijas grupâs. I grupas pacienti epidurâli saòçma glikokortikoîdu metilprednizolona sukcinâtu un ilgstoðas
darbîbas opioîdu morfîna hidrohlorîdu, II grupas pacienti saòçma lokâlo anestçtiíi bupivakaîna hidrohlorîdu un morfîna hidrohlorîdu, III
grupas pacienti saòçma metilprednizolona sukcinâtu un fentanîlu, IV grupas pacienti saòçma metilprednizolona sukcinâtu. Atsâpinâðana
bija ïoti laba visâs terapijas grupâs, bet metilprednizolona–morfîna grupâ mçs ieguvâm statistiski ievçrojami labâkus rezultâtus. Epidurâlais
metilprednizolons devâ 80 mg/dn atklâjâs kâ efektîva multimodâlâs preventîvâs atsâpinâðanas sastâvdaïa pçc ceïa endoprotezçðanas
operâcijâm. Salîdzinot ar ierasto bupivakaîna–morfîna kompozîciju, ir pierâdîts lîdzîgs vai pat vçl labâks efekts. Epidurâlais
metilprednizolons ir arî pierâdîjis savas imûnmodulçjoðâs un pretiekaisuma îpaðîbas, ietekmçjot akûtâs pçcoperâcijas iekaisîgâs fâzes
mediatorus – interleikînu-6 un C-reaktîvo olbaltumu un samazinot stresa hormona kortizola lîmeni pçcoperâcijas periodâ. Ðî pçtîjuma
novitâte ir glikokortikoîdu epidurâlâ izmantoðana tieði akûto pçcoperâcijas sâpju samazinâðanai ikdienas darbâ. Attîstot pçtîjumus par
metilprednizolona pretiekaisuma un imûnmodulçjoðâm îpaðîbâm, mçs vçlçtos uzlabot pacientu rehabilitâciju pçcoperâcijas periodâ.
Received 3 October 2008
